Viatris (VTRS) Research & Development (2020 - 2026)
Viatris (VTRS) posted quarterly Research & Development of $248.6 million for Q1 2026, up 11.98% year-over-year from $222.0 million in Q1 2025, and up 138.67% quarter-over-quarter from -$642.9 million in Q4 2025.
Viatris (VTRS) Research & Development (2020 - 2026) Analysis & Trends
Viatris' Research & Development history runs 7 years deep, the most recent figure standing at $248.6 million for Q1 2026.
- In Q1 2026, Research & Development rose 11.98% year-over-year to $248.6 million; the TTM figure through Mar 2026 stood at $74.9 million (up 48.02% YoY), while the FY2025 annual figure was $48.3 million, up 70.67% from the prior year.
- Research & Development for Q1 2026 stood at $248.6 million, up from -$642.9 million in the prior quarter.
- The five-year high for Research & Development was $662.2 million in Q4 2022, with the low at -$642.9 million in Q4 2025.
- The 5-year median for Research & Development is $199.0 million (2024), against an average of $111.4 million.
- Peak annual rise in Research & Development reached 1900.98% in 2024, while the deepest fall reached 708.59% in 2024.
- Viatris' Research & Development stood at $662.2 million in 2022, then slumped by 85.76% to $94.3 million in 2023, then sank by 708.59% to -$573.9 million in 2024, then declined by 12.02% to -$642.9 million in 2025, then soared by 138.67% to $248.6 million in 2026.
- Business Quant data shows VTRS's Research & Development at $248.6 million in Q1 2026, -$642.9 million in Q4 2025, and $250.4 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | R&D (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 43.71 Bn | 42.75 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 43.11 Bn | 39.45 Bn | 2.15 Bn | 970.00 Mn |
| 3 | Zoetis | 31.62 Bn | 29.94 Bn | 1.05 Bn | - |
| 4 | Takeda Pharmaceutical | 28.72 Bn | 22.92 Bn | 5.10 Bn | -1.05 Bn |
| 5 | United Therapeutics | 22.33 Bn | 19.67 Bn | 683.80 Mn | 146.30 Mn |
| 6 | Viatris | 18.83 Bn | 17.95 Bn | 1.46 Bn | 248.30 Mn |
| 7 | Neurocrine Biosciences | 15.62 Bn | 15.23 Bn | 935.80 Mn | 326.70 Mn |
| 8 | Elanco Animal Health | 12.10 Bn | 11.57 Bn | 798.00 Mn | 92.00 Mn |
| 9 | Dr Reddys Laboratories | 10.11 Bn | 9.94 Bn | - | - |
| 10 | Alkermes | 8.25 Bn | 7.60 Bn | 397.90 Mn | 154.36 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 248.30 Mn |
| Mar 31, 2026 | 248.60 Mn |
| Dec 31, 2025 | -642.90 Mn |
| Sep 30, 2025 | 250.40 Mn |
| Jun 30, 2025 | 218.80 Mn |
| Mar 31, 2025 | 222.00 Mn |
| Dec 31, 2024 | -573.90 Mn |
| Sep 30, 2024 | 198.40 Mn |
| Jun 30, 2024 | 204.10 Mn |
| Mar 31, 2024 | 199.70 Mn |
| Dec 31, 2023 | 94.30 Mn |
| Sep 30, 2023 | 211.20 Mn |
| Jun 30, 2023 | 10.20 Mn |
| Dec 31, 2022 | 662.20 Mn |
| Sep 30, 2022 | 174.90 Mn |
| Jun 30, 2022 | 162.60 Mn |
| Mar 31, 2022 | 142.30 Mn |
| Dec 31, 2021 | -413.80 Mn |
| Sep 30, 2021 | 152.10 Mn |
| Jun 30, 2021 | 147.70 Mn |